

Daniel G Stover

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1918352/daniel-g-stover-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

4,181
citations

27
h-index

64
g-index

135
ext. papers

5,848
ext. citations

7.6
avg, IF

4.89
L-index

#	Paper	IF	Citations
110	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.. <i>JAMA Network Open</i> , 2022 , 5, e2142046	10.4	1
109	CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, CLO22-033	7.3	0
108	Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth.. <i>Nature Biomedical Engineering</i> , 2022 ,	19	1
107	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e224304	10.4	4
106	Racial and Ethnic Disparities in Synchronous and Metachronous Bilateral Breast Cancer.. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022 , 1	3.5	0
105	Breast Cancer SurvivorsRTyphoid Vaccine Responses: Chemotherapy, Obesity, and Fitness Make a Difference.. <i>Brain, Behavior, and Immunity</i> , 2022 , 103, 1-1	16.6	0
104	Challenges and Gaps in Clinical Trial Genomic Data Management.. <i>JCO Clinical Cancer Informatics</i> , 2022 , 6, e2100193	5.2	0
103	Activity of Estrogen Receptor Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.. <i>Frontiers in Oncology</i> , 2022 , 12, 857590	5.3	1
102	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2134330	10.4	8
101	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. <i>Npj Breast Cancer</i> , 2021 , 7, 142	7.8	2
100	Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. <i>The Journal of Breast Health</i> , 2021 , 17, 371-377	1.5	0
99	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrightNess Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 603-608	13.4	19
98	Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e18739-e18739	2.2	0
97	Plasma circulating tumor DNA (ctDNA) fraction and real-world overall survival (rwOS) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e17035-e17035	2.2	0
96	Association of pathological complete response rates and TILs in triple-negative breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e12596-e12596	2.2	0
95	A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study. <i>Journal of Oncology</i> , 2021 , 2021, 9965583	4.5	2
94	Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e12528-e12528	2.2	0

93	Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS1102-TPS1102	2.2	0
92	Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e13056-e13056	2.2	
91	Racial and ethnic disparities among patients with breast cancer and COVID-19.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6500-6500	2.2	
90	Testing for clonal hematopoiesis of indeterminate potential in breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e24108-e24108	2.2	
89	Genomic features of rapid versus late relapse in triple negative breast cancer. <i>BMC Cancer</i> , 2021 , 21, 568	4.8	2
88	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. <i>Genome Medicine</i> , 2021 , 13, 89	14.4	0
87	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. <i>Annals of Oncology</i> , 2021 , 32, 787-800	10.3	85
86	Stromal Platelet-Derived Growth Factor Receptor-β Signaling Promotes Breast Cancer Metastasis in the Brain. <i>Cancer Research</i> , 2021 , 81, 606-618	10.1	12
85	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. <i>Cell Research</i> , 2021 , 31, 178-186	24.7	43
84	The COVID-19 & Cancer Consortium (CCC19) and Opportunities for Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100614	3.3	2
83	Socioeconomic and Surgical Disparities are Associated with Rapid Relapse in Patients with Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6500-6509	3.1	6
82	ASO Author Reflections: Disparities in Oncologic Surgery: The Problem We All Live with. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6510-6511	3.1	1
81	Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. <i>Menopause</i> , 2021 , 28, 642-649	2.5	5
80	De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 33	7.8	1
79	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 797-804	7.3	3
78	Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal Study. <i>Frontiers in Oncology</i> , 2021 , 11, 652683	5.3	
77	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021 ,	13.4	47
76	The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2522-2532	15.4	6

75	Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 183-188	4.4	1
74	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. <i>Npj Precision Oncology</i> , 2021 , 5, 83	9.8	0
73	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020 , 38, 761-766	24.3	12
72	Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. <i>BMC Cancer</i> , 2020 , 20, 445	4.8	3
71	Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. <i>Oncologist</i> , 2020 , 25, e1158-e1169	5.7	4
70	TTF-1 Positive Primary Small Cell Carcinoma of the Breast: A Case Report and Review of the Literature. <i>Frontiers in Endocrinology</i> , 2020 , 11, 228	5.7	7
69	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	18.8	0
68	Metastatic breast cancer patient perceptions of somatic tumor genomic testing. <i>BMC Cancer</i> , 2020 , 20, 389	4.8	2
67	The impact of granulocyte colony-stimulating factor use in patients with metastatic breast cancer treated with palliative chemotherapy: a single-institution retrospective review. <i>Supportive Care in Cancer</i> , 2020 , 28, 5537-5545	3.9	
66	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2556-2564	12.9	32
65	Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine. <i>Genes</i> , 2020 , 11,	4.2	2
64	Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. <i>World Journal of Surgical Oncology</i> , 2020 , 18, 11	3.4	7
63	A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. <i>Investigational New Drugs</i> , 2020 , 38, 1400-1410	4.3	12
62	Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience. <i>Investigational New Drugs</i> , 2020 , 38, 1605-1611	4.3	1
61	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. <i>Blood</i> , 2020 , 136, 56-58	2.2	1
60	Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e14004-e14004	2.2	
59	Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls. <i>The Journal of Breast Health</i> , 2020 , 16, 201-207	1.5	1
58	Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020 , 28, 3669-3677	3.9	15

57	Essentiality and Transcriptome-Enriched Pathway Scores Predict Drug-Combination Synergy. <i>Biology</i> , 2020 , 9,	4.9	3
56	Estrogen Receptor Beta (ER β) A Ligand Activated Tumor Suppressor. <i>Frontiers in Oncology</i> , 2020 , 10, 587386	5.3	18
55	Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study. <i>Breast Cancer Research</i> , 2020 , 22, 78	8.3	3
54	Adjuvant radiation therapy alone is associated with improved overall survival compared to hormonal therapy alone in older women with estrogen receptor positive early stage breast cancer. <i>Cancer Medicine</i> , 2020 , 9, 8345-8354	4.8	1
53	Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, 33-40	3	21
52	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, e20-e26		1
51	Identification of Alternatively-Activated Pathways between Primary Breast Cancer and Liver Metastatic Cancer Using Microarray Data. <i>Genes</i> , 2019 , 10,	4.2	4
50	Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019 , 9, 1208-1227	24.4	45
49	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4644-4655	12.9	41
48	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. <i>Cancer Cell</i> , 2019 , 35, 428-440.e5	24.3	239
47	Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 80	8.3	23
46	Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 510-510	2.2	4
45	Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13554-e13554	2.2	
44	Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12050-e12050	2.2	
43	Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	4
42	Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges. <i>Cancer Journal (Sudbury, Mass)</i> , 2018 , 24, 61-64	2.2	9
41	ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. <i>Clinical Cancer Research</i> , 2018 , 24, 2517-2529	12.9	19
40	Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 21-31	4.4	21

39	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2018 , 4, 10	7.8	58
38	Tumor fraction in cell-free DNA as a biomarker in prostate cancer. <i>JCI Insight</i> , 2018 , 3,	9.9	49
37	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 543-553	2.2	113
36	Chemotherapy-Exacerbated Breast Cancer Metastasis: A Paradox Explainable by Dysregulated Adaptive-Response. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	27
35	The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources. <i>Yearbook of Medical Informatics</i> , 2018 , 27, 211-222	4	9
34	BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. <i>PLoS Biology</i> , 2018 , 16, e2005756	9.7	31
33	Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. <i>Cancer Cell</i> , 2018 , 33, 985-1003.e7	24.3	113
32	Restoring Balance: Paraneoplastic Cerebellar Degeneration. <i>American Journal of Medicine</i> , 2017 , 130, e85-e87	2.4	3
31	Integrin-4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E2337-E2346	11.5	165
30	Identification of cancer genes that are independent of dominant proliferation and lineage programs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E11276-E11284	11.5	13
29	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017 , 8, 1324	17.4	314
28	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2016 , 17, 2367-2381	10.6	146
27	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016 , 22, 723-6	50.5	76
26	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. <i>Clinical Cancer Research</i> , 2016 , 22, 6039-6050	12.9	32
25	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016 , 529, 413-417	50.4	363
24	Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. <i>Current Oncology Reports</i> , 2015 , 17, 15	6.3	22
23	CDK7-dependent transcriptional addiction in triple-negative breast cancer. <i>Cell</i> , 2015 , 163, 174-86	56.2	268
22	Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. <i>Breast</i> , 2015 , 24 Suppl 2, S132-5	3.6	20

21	Morbidity and mortality revisited: applying a new quality improvement paradigm in oncology. <i>Journal of Oncology Practice</i> , 2015 , 11, e428-33	3.1	7
20	Simultaneous metastasis of melanoma and lung adenocarcinoma to hilar lymph nodes and pleural effusion after renal transplantation. <i>Cytopathology</i> , 2014 , 25, 342-4	1.3	2
19	Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 168-78	3.8	26
18	The effect of reducing maximum shift lengths to 16 hours on internal medicine internsReducational opportunities. <i>Academic Medicine</i> , 2013 , 88, 512-8	3.9	16
17	Flash mob research: a single-day, multicenter, resident-directed study of respiratory rate. <i>Chest</i> , 2013 , 143, 1740-1744	5.3	42
16	Intracardiac thrombus: diagnosis, complications and management. <i>American Journal of the Medical Sciences</i> , 2013 , 345, 391-5	2.2	35
15	Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2012 , 47, 82-7	4.4	6
14	Diverticulitis in a young man with hyper-IgE syndrome. <i>Southern Medical Journal</i> , 2010 , 103, 1261-3	0.6	6
13	Anti-N-methyl-D-aspartate receptor encephalitis in a young woman with a mature mediastinal teratoma. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1872-3	8.9	14
12	Caveat arthroplasty. <i>Journal of Arthroplasty</i> , 2009 , 24, 728-34	4.4	2
11	TGF-beta promotes cell death and suppresses lactation during the second stage of mammary involution. <i>Journal of Cellular Physiology</i> , 2009 , 219, 57-68	7	38
10	Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 93-6	8.9	26
9	Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1571-82	15.9	108
8	Autologous Stem Cell Transplant in Recurrent Diffuse Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early Lymphocyte Recovery and Transplant Outcome.. <i>Blood</i> , 2009 , 114, 3407-3407	2.2	2
7	Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. <i>Cancer Research</i> , 2008 , 68, 1809-19	10.1	110
6	Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. <i>Investigational New Drugs</i> , 2008 , 26, 339-45	4.3	1
5	Treatment of juvenile xanthogranuloma. <i>Pediatric Blood and Cancer</i> , 2008 , 51, 130-3	3	91
4	Presentation of a medullary endocrine neoplasia 2A kindred with Cushing's syndrome. <i>American Surgeon</i> , 2008 , 74, 659-61	0.8	4

- 3 A delicate balance: TGF-beta and the tumor microenvironment. *Journal of Cellular Biochemistry*, **2007**, 101, 851-61 4-7 109
- 2 Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF. *International Journal of Oncology*, **2002**, 21, 401-8 1 18
- 1 Machine learning predicts rapid relapse of triple negative breast cancer 1